The market for prescription anti-obesity medications (AOMs) is the most significant new pharmaceutical market in decades. In the next few years, the already spectacular growth of this market will be accelerated by new launches, including oral agents, development of both the out of pocket and the reimbursed markets, outcomes trials showing new benefits for current agents, and intense competition.
IQVIA will provide a forward looking, global guide to understanding and navigating this fast-moving environment, identifying the key levers and issues which will shape the market in the next five years.
We’ll explore:
Sarah Rickwood, VP, EMEA Thought Leadership, IQVIA.
John Clarke, Senior Principal, Global Primary Intelligence, IQVIA.
Alice Cinzia Perego, Offering Development Director, Global Launch Excellence, IQVIA.
Discover proven strategies and insights refined over more than 5,000 launches around the world.
.svg){kind=icon}
